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Abstract
Background: Data on premature coronary artery disease (CAD) are scarce. The Tehran Heart Center's Premature Coronary 
Atherosclerosis Cohort Study (THC-PAC) is the first study of its kind in the Middle East to assess major adverse cardiac events 
(MACE) in young CAD patients.
Methods: The cohort consists of CAD patients, males ≤ 45 years old and females ≤ 55 years old. The participants are 
residents of Tehran or its suburbs and underwent coronary angiography between June 2004 and July 2011. A 10-year 
follow-up, via either clinical visits or telephone calls at least once a year, was commenced in August 2012. The end point is 
considered MACE, encompassing death, myocardial infarction, stroke, new coronary involvement, percutaneous coronary 
intervention, and coronary artery bypass grafting.
Results: The cohort comprises 1232 eligible patients (613 [49.8%] males) at a mean age of 45.1 years (SD = 5.8). High 
frequencies of conventional risk factors, including hyperlipidemia (884 [71.8%]), hypertension (575 [46.7%]), positive family 
history (539 [43.8%]), cigarette smoking (479 [38.8%]), and diabetes mellitus (390 [31.7%]), were seen in the participants. 
The mean body mass index (BMI) of the enrolled patients was high (29.2 ± 4.8 kg/m2), and 532 (43.3%) and 440 (35.8%) of them 
were overweight and obese, respectively. The females’ BMI was higher (30.4 ± 5.3 vs. 28.0 ± 3.9 kg/m2; P < 0.001) and they had 
a greater mean abdominal circumference (99.9 ± 13.5 vs. 98.1 ± 9.3 cm; P = 0.035). Between August 2012 and August 2013, 
follow-up was successful in 1173 (95.2%) patients (median follow-up duration = 55.3 months, 95%CI: 53.5-57.0 months).
Conclusion: Our younger patients with CAD had a high frequency of risk factors compared to the same-age general population 
and all-age CAD patients, which may predispose them to higher incidence of recurrent MACE.
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Introduction
Coronary artery disease (CAD) is predominantly seen 
in the last decades of life. However, it is well known that 
coronary atherosclerosis begins when individuals are 
young. Even though it has been estimated that only about 
10% of patients with documented CAD are less than 45 
years old1 and about 2% to 6% of all infarctions occur in 
this age group,2 autopsies of young individuals have shown 
that about 50% of those under 34 years of age have intimal 
atherosclerosis.3 Therefore, patients with overt premature 
CAD represent the “tip of the iceberg”. Furthermore, in the 
coming years, increases in the prevalence of type II diabetes 
and metabolic syndrome in young adults, related to the 
increasing frequency of obesity, will result in a rise in the 
number of premature CAD patients, which will be a critical 
and challenging medical issue.4
The high prevalence of premature CAD and high mortality 
rates due to CAD are two important characteristics of this 
group of diseases in developing countries.5 Unfortunately, 
while owing to epidemiologic transition, the prevalence of 
CAD in developed countries is decreasing, this prevalence 
is notably increasing in low- and mid-income countries.6 
This means that developing countries with limited financial 
resources will face many obstacles in coping with the 
prevention, screening, and treatment of their CAD patients. 
This challenge is bound to be even more formidable in the 
future because the CAD prevalence in a considerable number 
of developing countries is on the rise in earlier years of life 
and as such severely impacts workforce productivity.6 
Premature CAD can have devastating individual, familial, 
and social consequences. Despite the alarming rise in 
premature CAD in developing countries, surprisingly, there 
is a dearth of relevant high quality data from many of these 
countries.1, 4 Reducing the prevalence of premature CAD by 
preventive measures requires knowledge of the relevant risk 
factors and ways to control them. Unfortunately, most of the 
knowledge in this regard comes from studies conducted in 
Western countries. Different societies have diverse lifestyles, 
nutrition, habits, exposures, socioeconomic status, and 
cultures which may give rise to dissimilar types of risk factors 
and differential effects of preventive measures. In other 
words, the severity and relevance of risk factors may vary 
from one population to another, and the association between 
risk factors and disease in different populations needs to be 
ascertained. Consequently, to have a better understanding of 
their own risk factors for CAD development and for adverse 
events thereafter, countries are recommended to conduct 
their own large-scale cohort studies so as to determine which 
factors are most important in their own settings and to what 
extent. Only then will it be possible to make appropriate 
plans and take suitable preventive measures. Thus, we 
designed the current cohort study to follow up documented 
premature CAD patients to assess the relevant risk factors 
for developing major adverse cardiac events (MACE) after 
the development of premature atherosclerosis and scrutinize 
the progress of CAD in young adults. 
Methods
Design and Subjects
Tehran Heart Center (THC) is a tertiary heart hospital and 
one of the largest cardiac centers in the Middle East. This 
center is affiliated to Tehran University of Medical Sciences 
and serves people with cardiovascular diseases referred 
from all around Iran. The participants of the current study 
(Tehran Heart Center’s Premature Coronary Atherosclerosis 
Cohort [THC-PAC]) were included from a group of young 
individuals who had been previously recruited in a genetic 
study at THC on premature CAD. That group consisted of 
3980 individuals (1511 [38.0%] males ≤ 45 years old and 
2469 [62%] females ≤ 55 years old) who consecutively 
underwent coronary angiography between June 2004 and 
July 2011. Since the aim of the THC-PAC cohort study is 
to identify factors responsible for developing MACE in 
premature CAD patients, its participants are premature 
CAD patients under long-term follow-up. Accordingly, 
from the above patient population, individuals residing in or 
near Tehran (the capital city of Iran) with a first abnormal 
coronary angiography proving CAD were enrolled. CAD 
was defined as at least ≥ 50% luminal stenosis in individual 
epicardial vessels. A 10-year follow-up through clinical visits 
or telephone calls at least once a year of all the participants in 
the THC-PAC study was commenced in August 2012. 
End Points
MACE is the end point of this cohort study and is defined 
as death (whether cardiac or non-cardiac); documented 
new myocardial infarction (MI) defined as symptoms of 
cardiac ischemia associated with either ST elevation on 
the electrocardiogram (≥ 0.2 mV in leads V1, V2, and V3 
and ≥ 0.1 mV in the other leads) or without ST elevation 
accompanied by a rise in cardiac enzymes (troponin or creatine 
kinase-MB); new coronary artery involvement defined as at 
least a new ≥ 50% luminal stenosis in an epicardial vessel 
besides previously detected lesions confirmed by coronary 
angiography; stroke (confirmed by a neurologist); candidacy 
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for percutaneous coronary intervention (PCI); or candidacy 
for coronary artery bypass graft surgery (CABG) during the 
follow-up period. If a patient suffers more than one event, 
the one that occurs first is considered the end point. The PCI 
or CABG procedures performed after the early stages of the 
first diagnosis of CAD, as the early treatment strategy, are 
not regarded as MACE. 
Follow-Up Methods
To follow up the participants effectively and with the 
highest response rate, we devised a well-elaborated follow-
up protocol. According to the protocol, first, a list of eligible 
patients was extracted from the Angiography Databank of 
THC. Then, a trained nurse, who was previously involved 
in other telephone follow-up studies, was allocated for 
calling the patients. Based on the experience from several 
telephone follow-ups having already been done at THC, a 
team of researchers including a cardiologist, a psychiatrist, 
and an epidemiologist prepared a protocol for the nurse to 
teach her how to speak with the patients (or their family 
members) and how to obtain the most reliable information. 
We considered various scenarios and prepared a different 
strategy for every single one of them. The first 20 calls were 
recorded and were checked by the research team. After 
analyzing the recorded talks and discussing the results, the 
researchers and the nurse shared their opinions to improve 
the telephone call protocol. We called the patients on their 
home or cell phone lines, collected at the time of recruitment 
in the initial genetic study, every day between 10.00 and 
18.00, excluding weekends. If we failed to reach the patients 
after three times calling on three different days, we extended 
the calling time from 8:00 to 22:00 on non-weekend days. 
We contacted those whom we could not reach by telephone 
on two different days between 8:00 and 22:00 during the 
weekends or holidays. We sent an invitation, twice in two 
successive weeks, in the form of a short text message to the 
cell phone of those participants who failed to respond to the 
calls for seven times. If we did not receive any response 
within a week, we sent a written invitation letter to their home 
address asking them to call a certain phone number. After a 
further three weeks, to trace those who did not respond to the 
telephone calls, cell phone messages, and letters, we checked 
the THC medical records to find whether they had referred to 
the outpatient clinics or whether they had been admitted to 
the hospital. Finally, we referred to the remaining patients’ 
addresses, registered before they had undergone angiography 
at THC. For door-to-door follow-up, we thought up different 
strategies to increase the success rate. Some of the patients 
missing to follow-up had moved into new residences; to 
obtain their new addresses, we referred to their neighbors, 
family members, or adjacent shops.  For those who were 
still living at their previously given addresses but their street 
names, building names, or building registration numbers had 
changed, we referred to the municipality or local real estates 
or inquired their whereabouts from the residents of the same 
neighborhood. In some instances, we referred to County 
Offices or Health House Offices to find the patients through 
their records.
Data Collection
THC enjoys several high-quality databanks, including 
the Angiography Databank. The patients’ baseline data at 
the time of the initial diagnosis with premature CAD were 
retrieved from the databank. At THC, the demographic, 
clinical, and risk factor data of all the patients who undergo 
coronary angiography are routinely collected by trained 
physicians in the outpatient and inpatient settings. The 
threshold for defining risk factors has already been explained 
elsewhere.7 The day before catheterization, two expert 
research nurses check and revise all the collected data via 
face-to-face interviews with the patients. Then, the collected 
data are entered by a trained operator via a secure password-
protected hospital network. This process is supervised by a 
databank manager, and at least 5% of the patients’ medical 
records are randomly selected by the manager to evaluate the 
accuracy of the data. 
Even though efforts are made to obtain all the required data 
at each follow-up call, all the patients are requested to visit 
the premature CAD clinic too. According to the protocol of 
this cohort study, clinical visits are to be done at least once 
a year as of 2012. At the first visit (2012), informed consent 
was obtained from all the participants, and a blood sample 
was drawn for further laboratory studies. At each clinical 
visit, the patients are to be seen by a cardiologist and a general 
practitioner. Clinical examinations, medical history takings, 
and additional measurements of risk factors are conducted 
and information about how to deal with risk factors is given to 
the patients. If the individuals need any further diagnostic or 
therapeutic procedures, proper measures are offered to them 
or they are referred to relevant specialists (e.g. interventional 
cardiologists, cardiac surgeons, and psychiatrists) for further 
management. Useful information on cardiac risk factors, 
physical activities, different treatment strategies, cardiac 
procedures, job stress, anxiety, and smoking cessation has 
been printed in different booklets and are offered to those 
who visit the clinic. The participants are also asked to fill 
in different standardized questionnaires for the evaluation of 
depression, anxiety, job stress, physical activity, and quality 
of life at baseline and each subsequent clinical visit. 
Statistical Analysis
Descriptive methods will be provided for the qualitative and 
quantitative variables. The continuous data will be reported 
with mean and standard deviation (SD) or median with 25th 
and 75th percentiles for the normal and skew-distributed 
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variables. The normality or skewness of the data will be 
evaluated using the mentioned descriptive statistics as well 
as applying histograms and box plots. These quantitative 
variables will be compared between the groups using the 
Student t or Mann-Whitney U test (for two independent 
groups) and the one-way analysis of variance (ANOVA) or 
Kruskal-Wallis test (for more than two independent groups). 
The qualitative variables will be described with frequency 
and percentage and will be compared between the groups 
using the chi-square or Fisher exact test. The incidence rate 
of MACE will be computed for descriptive purposes. Time 
to MACE events will be described using survival curves, 
which will be estimated through the Kaplan-Meier estimator, 
and 95% confidence intervals (CI) for the survival rates will 
be computed using the log-transformed method.
The association between the variables and MACE events 
will be evaluated using the Cox proportional hazards 
(PH) model and will be reported through the hazards ratio 
with a 95%CI. A backward stepwise Cox PH model with 
probabilities 0.05 and 0.1, as entry and removal probabilities, 
will be used to find the multiple predictors of MACE 
incidence. All variables with p values less than 0.2 in the 
univariate analysis will be candidated to enter the prediction 
model. The PH assumption will be assessed through the 
chi-square test of correlation coefficient between scaled 
Schoenfeld residuals and transformed survival time. In case 
of violation of the PH assumption, parametric models may 
be drawn upon.
In the presence of time-dependent covariates, an 
extended Cox PH model will be used. Also, the extended 
Cox PH model in a multi-state setting will be employed 
to model the recurrence of some MACE components. The 
MACE components will be analyzed in a competing risks 
setting and will be described through cumulative incidence 
function. A sub-distribution hazard model will be utilized 
to find multiple predictors of the MACE components in the 
presence of competing events.
The models stated above will result in valid and unbiased 
results when the data are “missing completely at random” 
(MCAR) or “missing at random” (MAR). The existence of 
missing data for some variables in the analysis, when data 
are missing not at random, will lead to biased estimates. To 
evaluate the impact of the missing data, sensitivity analysis 
will be conducted.
Results
From an initial population source of 3980 individuals, 
1946 (48.9%) patients had documented premature CAD. 
Of these CAD patients, 1447 (74.4%) individuals were 
residents of Tehran or its suburbs, of whom 215 did not meet 
the inclusion criteria and were excluded from the study. 
Therefore, 1232 eligible patients were included in the THC-
PAC study for the 10-year follow up according to the study 
protocol.  
At baseline, the mean age of the enrolled patients was 45.1 
years (SD = 5.8), and 613 (49.8%) of them were male. The 
characteristics of the patients based on the baseline visit are 
depicted in Table 1. Concerning conventional risk factors, 
hyperlipidemia (884 [71.8%]) was the most frequent risk 
factor, followed by hypertension (575 [46.7%]), positive 
family history (539 [43.8%]), cigarette smoking (479 
[38.8%]), and diabetes mellitus (390 [31.7%]). Among the 
patients, 160 (13.0%) individuals reported current opium use. 
Forty-one (3.3%) patients had no risk factor at all.  The initial 
mean body mass index (BMI) of the enrolled patients was 
29.9 kg/m2 (SD = ± 4.8), and 532 (43.3%) and 440 (35.8%) 
of them were overweight (BMI ≥ 25 and < 30 kg/m2) and 
obese (BMI ≥ 30 kg/m2), respectively. The female patients 
had a significantly higher mean BMI than the males (30.4 ± 
5.3 vs. 28.0 ± 3.9 kg/m2, mean difference = 2.4, 95%CI: 1.9-
2.9; P < 0.001) and their mean abdominal circumference was 
greater (99.9 ± 13.5 vs. 98.1 ± 9.3 cm, mean difference = 1.8, 
95%CI: 0.1-3.4; P = 0.035).
Concerning the initial treatment, as is illustrated in Table 
1, from the 1232 enrolled patients, 406 (33.5%) were treated 
medically, 530 (43.7%) underwent PCI, and 296 (24.4%) 
underwent CABG.   Furthermore, the patients with single- 
or two-vessel coronary involvement were more frequently 
treated by PCI, while those with three-vessel or left main 
coronary involvements were more often treated by CABG.
Between August 2012 and August 2013, from the 1232 
enrolled patients, 1173 (95.2%) individuals were followed 
up successfully. A schematic presentation of the follow-
up process is given in Figure 1. Telephone follow-up was 
successful in 1110 (90.1%) individuals.  Among the non-
responders to telephone calls, 10 (0.1%), 17 (1.4%), 17 
(1.4%), and 19 (1.5%) patients were successfully followed 
up via short messages to cell phones, invitation letters by 
mail, door-to-door survey, and checking hospital records, 
respectively. Of 95 patients who were followed up by door-
to door survey, 17 (17.9%) individuals were found at their 
given addresses, 35 (36.9%) patients had moved to other 
places, and 43 (45.3%) patients could not be found.
A comparison between the initial recommendations by 
treating physicians following coronary angiography and the 
treatment which the patients received is presented in Table 
2. As is shown in this table, in 79.7% of the patients in the 
medical treatment, 84.0% of the PCI, and 78.2% of CABG 
groups, the initial recommendations were the same as the 
initially given treatments.
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Table 1. Patients Characteristics based on their baseline visit (angiography time)* 
All Patient 
(n = 1232)
Medical Treatment 
(n = 406)
PCI
(n = 530)
CABG
(n = 296)
P value
Age (y) 45.11±5.76 45.34±6.09 44.63±5.80 45.64±5.16    0.034
Sex    0.152
Male 613 (49.8) 187 (46.1) 278 (52.5) 148 (50.0)
Female 619 (50.2) 219 (53.9) 252 (47.5) 148 (50.0)
Risk Factors
Positive Family History 539 (43.8) 168 (41.4) 233 (44.0) 138 (46.6)    0.381
Hypertension 575 (46.7) 214 (52.7) 225 (42.5) 136 (45.9)    0.007
Hyperlipidemia 884 (71.8) 279 (68.7) 390 (73.6) 215 (72.6)    0.242
Diabetes Mellitus 390 (31.7) 123 (30.3) 162 (30.6) 105 (35.5)    0.268
Cigarette Smoking    0.457
Never Smoked 753 (61.1) 259 (63.8) 309 (58.3) 185 (62.5)
Former Smokers 93 (7.5) 26 (6.4) 45 (8.5) 22 (7.4)
Current Smokers 386 (31.3) 121 (29.8) 176 (33.2) 89 (30.1)
Opium Usage 160 (13.0) 60 (14.8) 58 (10.9) 41 (13.9)    0.175
No Risk Factor 41 (3.3) 13 (3.2) 20 (3.8) 8 (2.7)    0.702
BMI (kg/m2) 29.18±4.79 29.51±5.22 28.99±4.52 29.07±4.63    0.241
BMI Categories    0.185
Underweight 12 (1.0) 5 (1.2) 5 (0.9) 2 (0.7)
Normal 244 (19.9) 85 (21.1) 97 (18.3) 62 (20.9)
Overweight 532 (43.3) 153 (38.1) 251 (47.4) 128 (43.2)
Obese 440 (35.8) 159 (39.6) 177 (33.4) 104 (35.1)
Metabloic Syndrome 590 (47.9) 190 (32.2) 248 (42.0) 152 (25.8)    0.932
Triglyceride (mg/dl) 203.37±127.17 193.16±110.12 207.14±138.40 210.47±127.45    0.309
Cholesterol (mg/dl) 196.51±51.67 195.48±50.33 194.17±53.30 202.21±50.16    0.092
LDL (mg/dl) 119.95±42.61 119.02±41.96 118.10±42.84 124.21±42.90    0.122
HDL (mg/dl) 41.09±11.01 42.25±11.27 40.37±10.95 40.75±10.67    0.036
FBS (mg/dl) 127.64±61.01 127.35±62.75 124.92±56.30 132.79±66.01    0.580
Creatinine (mg/dl) 0.97±0.44 1.00±0.70 0,.95±0.23 0.96±0.24    0.886
EF (%) 52.55±10.01 52.93±9.99 52.40±10.16 52.26±9.81    0.638
Abdominal Circumference (cm)    0.360
Male 98.11±9.33 99.34±10.89 97.72±8.14 97.44±9.42
Female 99.87±13.49 100.24±12.28 100.06±14.71 99.00±12.6
Blood Pressure (mmHg)
Systolic 127.16±18.23 128.82±17.01 125.30±19.11 128.59±17.79    0.028
Diastolic 80.88±18.58 81.76±11.13 81.21±25.02 79.09±9.64    0.293
Heart Failure 5 (0.4) 2 (0.5) 1 (0.2) 2 (0.7)    0.732
Renal Failure 6 (0.5) 5 (1.3) 0 1 (0.4)    0.024
Recent MI 533 (45.6) 167 (43.2) 251 (49.5) 117 (42.1)    0.035
No. of Involved Vessels < 0.001
SVD 559 (45.4) 238 (58.6) 286 (54.0) 35 (11.8)
2VD 342 (27.8) 102 (25.1) 166 (31.3) 74 (25.0)
3VD 331 (26.9) 66 (16.3) 78 (14.7) 187 (63.2)
Left Main Coronary Involvement 22 (1.8) 0 0 22 (7.4) < 0.001
*Data are presented as mean±SD or n (%)
PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass grafting; BMI, Body mass index; LDL, Low-density lipoprotein; HDL, High-
density lipoprotein; FBS, Fasting blood sugar; EF, Ejection fraction; MI, Myocardial infarction; SVD, Single-vessel disease; 2VD, Two-vessel disease; 3VD, 
Three-vessel disease
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Table 2. Comparison between initial recommendations by treating physicians and initial treatment
Initial Treatment (n=1232)
TOTAL P value
Medical Treatment (n=406) PCI (n=530) CABG (n=296)
Recommendations by Treating Physicians < 0.001
Medical Treatment 310 (79.9) 52 (13.4) 27 (6.9) 389
PCI 63 (12.0) 442 (84.0) 21 (4.0) 526
CABG 33 (10.4) 36 (11.4) 248 (78.2) 317
*Data are presented as n (%)
PCI, Percutaneous coronary intervention; CABG, Coronary artery bypass grafting
Figure 1. Scheme of the follow-up (F/U) process
Discussion
In developing countries, higher prevalence of premature 
CAD and higher mortality due to cardiovascular disorders 
warrant special consideration.5 In comparison with the 
Western population, it has been estimated that CAD occurs at 
least 10 years earlier in South Asians.8 The current literature 
contains a number of studies on cardiovascular risk factors 
in young adults, with the bulk of the research being confined 
to Western countries. Some important studies in this regard 
are the Bogalusa Heart Study, started in 1972 in Bogalusa, 
Louisiana, United States, with 3524 children ages 5-14 
years;9 Coronary Artery Risk Development in Young Adults 
(CARDIA), started in 4 field centers in the United States 
in 1985-86 with 5115 normal participants aged between 
18 and 30 years;10 Atherosclerosis Risk in Young Adults 
(ARYA), comprising two cohorts of young adults in the 
Netherlands (the Utrecht cohort including 750 young adults 
born between 1970 and 1973 and the Hague cohort including 
262 young adults born between 1963 and 1968);11 Muscatine 
study, initiated in 1970 in Muscatine, Iowa, United States, 
participating 11377 students from Muscatine in 6 biennial 
school survey examinations;12 Atherosclerosis Risk Factors 
in Male Youngsters (ARMY), commenced in Austria in 
2001, in a sample of 141 white males homogenous in age 
and sex (ages 17-18 years);13 National Health and Nutrition 
Examination Survey (NHANES), started in early 1960s in 
the United States, examining a nationally representative 
sample of about 5000 persons each year;14 Pathological 
Determinants of Atherosclerosis in Young (PDAY), initiated 
in 1985 in the United States, investigating the arteries of 
about 3000 young people who died between 15 and 34 years 
of age in 15 centers;15 the Northern Ireland Young Heart 
Project, started in 1989 in Northern Ireland, recruiting 1015 
school children ages 12-15 years;16 Cardiovascular Risk in 
Young Finns, initiated in late 1970s in Finland, including 
3596 boys and girls in 6 age cohorts (ages 3, 6, 9, 12, 15, 
and 18 years);17 and Minneapolis Children’s Blood Pressure 
Study, launched in 1978 in Minneapolis, United States, 
surveying 9977 black and white children between 6 and 9 
years of age.18 Unfortunately, since most of these studies 
have been mainly confined to the Western population, their 
results cannot always be generalized to other populations. 
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Furthermore, the settings of all these cohorts are different 
from that of the THC-PAC study inasmuch as the age of 
their participants was different and none of their recruited 
individuals had angiographically documented CAD.
There is also a study by Cole and colleagues,2 who followed 
up 843 CAD patients 40 years of age who underwent 
coronary angiography between 1975 and 1985. Although 
their study is the closest study to ours and they followed up 
premature CAD patients too, our settings differ in several 
aspects. First, the ages of the participants are not the same: 
whereas we recruited CAD patients consisting of males ≤ 45 
years old and females ≤ 55 years old, Cole et al. followed up 
CAD patients under 40 years of age whether male or female. 
Second, while we considered MACE as the end point of our 
study and also assessed some other variables aside from 
MACE, they considered only death as the end point. Third, 
the Cole et al. study followed up patients who underwent 
angiography between 1975 and 1985, since which period the 
treatment of cardiovascular disorders has advanced a great 
deal. That our study is more recent means that the findings are 
closer to present treatment measures. Fourth, they included 
all premature CAD patients, while we included only those 
with first-time premature CAD presentation. Therefore, 
some of their patients may already have had CAD, but since 
their end point was only death, this would not affect their 
study. In contrast, what we probed into was first-time MACE 
after CAD diagnosis and, accordingly, we recruited only 
first-time CAD patients to ensure that our cohort had not 
already developed post-CAD MACE. Fifth, that study was a 
cross-sectional study, while the THC-PAC study has a cohort 
design and we are to follow up the participants at yearly 
intervals. Sixth, that study was done in a Western setting 
and we studied on Eastern individuals. Western and Eastern 
societies have considerably diverse genetic backgrounds and 
dissimilar exposures, and these differences may give rise to 
a noticeable variation in the development and progression 
of CAD. Hence, studies on the Eastern population are of 
great importance and are highly recommended. To the best 
of our knowledge, not only is the THC-PAC study the largest 
cohort study of its kind in the Middle East, but also it is the 
only cohort in which the participants are young adults with 
angiographically documented CAD.
For the THC-PAC study, MACE was considered as the end 
point. The term “MACE” is almost the most commonly used 
composite end point in cardiovascular studies. Although 
the term “MACE” originated in the mid 1990s and it has 
been strictly used to indicate in-hospital complications 
due to PCI and then used in other cardiovascular settings, 
there is no standard definition for it.  Even in studies with 
a very specific question, there is no consensus definition of 
MACE.19 With the differently defined MACE, it is likely that 
widely different results and conclusions are obtained even 
within a single study. This end point is used to reflect both 
the safety and effectiveness of various treatment approaches. 
“Safety” signifies security, and “effectiveness” denotes the 
risk for lesion recurrence. For “safety”, different variables 
focused on by various studies are comprised of death, MI, 
acute coronary syndrome, stroke, and heart failure; and for 
“effectiveness” they comprise new coronary involvement 
or stent thrombosis in angiographic follow-up evaluation, 
PCI, and CABG. Depending on the designs of the various 
studies, researchers have employed different combinations 
of these variables. In our study, we defined MACE as the 
most commonly used definition in the literature, which 
includes death, MI, stroke, new coronary involvement, PCI, 
or CABG. Concerning death, the majority of the studies on 
PCI complications have only included mortalities which 
are obviously due to cardiac problems, while in general 
cardiovascular settings, they have mainly included all-cause 
mortality. In our study, we considered all-cause mortality as 
MACE.
An important feature of our study is its inclusion of a 
large proportion of women. Much of our current knowledge 
on preventive measures, diagnostic plans, and treatment 
strategies is based on studies conducted predominantly 
in men. A large number of analyses have underscored the 
underrepresentation of women in cardiovascular studies, and 
the proportion of women enrolled in many studies fails to 
reflect their actual representation in the disease populations 
receiving treatment accurately.20 Even so, these studies have 
resulted in guidelines which in reality are appropriate for 
men only and whether this constitutes sufficient support for 
guidelines in women is open to debate. 
Concerning conventional risk factors, the premature CAD 
patients in this study had a high prevalence rate. When 
we compared our data to the same-aged Iranian general 
population data,21 there was a large excess of individuals who 
were hypertensive (46.7% vs. 13.2%), were smokers (38.8% 
vs. 9.4%), and had diabetes (31.7% vs. 9.8%). In our study, 
hyperlipidemia was defined as either hypercholesterolemia 
or hypertriglyceridemia. Official reports of the risk factor 
surveillance in Iran21 suggest that 33.1% of the same-aged 
Iranian population has hypercholesterolemia and 19.3% has 
hypertriglyceridemia. In our study, we found an even higher 
prevalence rate compared to the summation of those types of 
dyslipidemia in the general population (71.8% vs. 52.4%). 
Furthermore, when we compared the current data with those 
from another study done on 37358 CAD patients from all-
age groups who underwent coronary angiography at THC 
between 2005 and 2010,22 there were also some differences 
in the prevalence of risk factors. Premature CAD patients 
in the THC-PAC study were less hypertensive (46.7% vs. 
53.3%) and had higher prevalence of a positive family 
history of CAD (43.8% vs. 21.7%) but had largely the same 
frequency of cigarette smoking and diabetes histories (38.8% 
vs. 39.5%, and 31.7% vs. 31.4%, respectively) and had a 
lower prevalence of opium usage (13.0% vs. 18.6%). The 
most noteworthy observation here is that our premature CAD 
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patients had twice more often a positive family history than 
the CAD patients of all ages combined. It implies the great 
impact of this risk factor on developing CAD in younger age 
and the importance of conducting relevant genetic studies. 
Family history is representative of the interaction between 
genetic and environmental factors and its relevant studies 
are the most accessible means to measure the inherited 
component of CAD. Therefore, a considerable part of the 
THC-PAC study is bound to be focused on a detailed family 
history and genetic assessment of the participants. 
In another study, by Reibis et al.,23 risk factors between 
5725 young (men aged < 55 years and women aged < 65 
years) and 9656 older CAD patients were compared. The 
cut-off point of age for defining young patients in that study 
was 10 years higher than ours. In their study, cigarette 
smoking, family history, and hyperlipidemia in the young 
and hypertension and diabetes in the older CAD patients 
stood out. Also in that study, 92.7% of the young patients 
were hyperlipidemic and 71.4%, 43.6%, 31.5%, and 23.5% 
of them had a history of hypertension, positive family history, 
cigarette smoking, and diabetes, respectively. 
In our study, the mean BMI of our patients was high. While 
the mean BMI of the same-aged general population in Iran 
is 24.9 kg/m2, it was 29.2 kg/m2 in the TCH-PAC patients. 
An official report21 showed that 43.7% of the same-aged 
Iranians were either overweight or obese, but this figure was 
substantially higher in our patients (79.1%). Iranian women 
have a higher BMI than men,21 which was also evident in 
our patients. However, both men and women in our study 
had a significantly higher BMI than their counterparts in the 
general population (males = 28.0 vs. 23.9 kg/m2; females = 
30.4 vs. 25.7 kg/m2).  Similar to most countries in the Middle 
East,24 Iranian women are less physically active than men 
and are more obese, which may predispose them to CAD 
development.22 The frequency of low physical activity in the 
Iranian population is 24.3% in men and 46.3% in women. 
The mean daily physical activity has been estimated to be 
189.0 minutes in men and 78.8 minutes in women.21 
Another significant finding in the THC-PAC study is 
the high prevalence of central obesity. In the same-aged 
Iranian population, the mean abdominal circumference 
has been estimated to be 83.8 cm in men and 82.8 cm in 
women,21 while they were 98.1 cm and 99.9 cm in our study, 
respectively. 
Some limitations of the THC-PAC study need due 
consideration. The participants of this study were recruited 
from a source already enrolled for a genetic study in young 
CAD patients, and different age criteria were applied for 
men and women to define “premature”, based on the known 
differences in age-related incidence rates between the sexes. 
This has led to an overrepresentation of women, which, 
however, can be adjusted for by stratification by sex, and 
has the advantage of yielding reliable estimates of risk in 
women. Also, we recruited only patients who were referred 
to THC and were the residents of Tehran or its vicinity. Iran 
is a multicultural country with different ethnic groups. It is 
probable that most of the recruited patients belong to some 
particular ethnicities, which can affect the results of the 
study. Tehran is a metropolitan city the residents of which are 
from different parts of the country with different ethnicity 
backgrounds. Loss to follow-up is a drawback in cohort 
studies but was low in our study thanks to our elaborate 
methods to locate patients.
Conclusion
The prevalence rates of all conventional risk factors for 
CAD were significantly higher in our sample of young Iranian 
CAD patients than in the Iranian general population. This 
included a high prevalence of hyperlipidemia, hypertension, 
positive family history, cigarette smoking, diabetes mellitus, 
and obesity. Our finding implies that these young CAD 
patients are at great risk for developing MACE, which is the 
subject of subsequent analyses. It also emphasizes the urgent 
need for dedicated care for these patients, which should 
particularly focus on weight management and exercise in 
women.
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